Document is current
Any future updates will be listed below
-
Authors
Esposito, Mark http://orcid.org/0000-0002-5724-4087
Ganesan, Shridar
Kang, Yibin http://orcid.org/0000-0002-1626-6730
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R01 CA212410)
- License Information
-
More Information
Article History
Received: 20 August 2020
Accepted: 5 February 2021
First Online: 24 March 2021
Competing interests
: M.E. holds equity interest and a management position in KayoThera, a company developing cancer therapeutics. Y.K. holds equity interest in KayoThera and Firebrand Therapeutics and is a member of the scientific advisory boards of KayoThera, Firebrand Therapeutics and Cytocares. Y.K. has consulted for Merck, Amgen and Ono Pharma and has previously received funding support from Merck, Amgen, Johnson & Johnson, Janssen, Glycomimetics and Ono Pharma. S.G. has consulted for Merck, Roche, Foundation Medicine, Foghorn Therapeutics, Novartis, Silagene, EQRX and Inspirata, has received research funding from M2GEN and has equity interest in Inspirata and Silagene.
